News

Expands the sites’ Process Development, Process Characterization and Analytical Services and adds approximately 145 skilled positions by 2024 Research Triangle Park, North Carolina — FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announced an expansion of its BioProcess Innovation Center (BIC) in Research Triangle Park (RTP). Through the expansion, FUJIFILM Diosynth Biotechnologies will add approximately 145 skilled positions including researchers and scientists to the RTP site by 2024. The expansion will double FUJIFILM Diosynth Biotechnologies’ capacity to support Process Characterization programs and complements the enhanced and now operational capabilities at FUJIFILM Diosynth Biotechnologies’ UK facility, announced in December 2020.  In addition, this expansion will allow FUJIFILM Diosynth Biotechnologies to better support its partners in discovering the attributes that make each protein unique and better guide clinical process development to create more robust

Fujifilm Also Congratulates the 2021 Fellowship Recipients CAMBRIDGE, Mass. — FUJIFILM Holdings America Corporation (Fujifilm), today announced that it has renewed its commitment to the Fujifilm Fellowship fund at Harvard Medical School (HMS) to advance education and research in the field of translational medicine, the process of applying basic research in the laboratory for new therapeutic development. The gift will support up to 8 additional Ph.D. candidates at HMS through 2024. Established in 2019, the fellowship program is designed to equip young scientists with the specialized skills needed to translate their research findings into cutting-edge medical solutions for patients. Harvard recently named Kailyn Doiron and Kanae Sasaki the newest Fujifilm Fellow recipients. They follow in the footsteps of 11 previous Ph.D. candidates at HMS who have received Fujifilm Fellowships, which awards two years of research funding to promising students from across the nine HMS-based life sciences Ph.D. programs. HMS leadership

The Texas site is the largest single-use CDMO production campus in North America Adds approximately 150 skilled positions to the site by 2024 and is supported by the State of Texas through a $1.5 million Enterprise Fund Award   COLLEGE STATION, Texas, FUJIFILM Diosynth Biotechnologies,  a world-leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announced an expansion of its single-use manufacturing campus in College Station through the addition of a new cGMP production facility that will double the Company’s advanced therapy and vaccine manufacturing capacity in the U.S. This investment is supported by a $1.5 million Texas Enterprise Fund Award to support the creation of approximately 150 skilled positions including manufacturing and operations by 2024. The investment of approximately $300 million for facility construction is part of a previously announced $850 million global capital investment package

-Expanding cell culture media production capacity to meet the increasing demand for biopharmaceuticals -Enhancing global production structure with modern manufacturing sites in Japan, the U.S. and Europe TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) begins operations at its new, state-of-the-art cell culture media manufacturing facility located in Tilburg, Netherlands to meet an increasing global demand for biopharmaceuticals. Funded through a focused investment in an existing Fujifilm European facility, the new facility manufactures products of FUJIFILM Irvine Scientific, Inc., a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The facility provides state-of-the-art life science manufacturing and joins locations in the U.S. and Japan to enable increased production capacity of cell culture media products; acting as a hub for both European and global markets. The strategic investment will enhance the Company’s support to customers with their drug

New center brings local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development SANTA ANA, California: FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the establishment of an Innovation and Collaboration Center in Suzhou New District, China. Through this new center, experts will collaborate with customers to design upstream cell culture processes that meet their biomanufacturing needs. In the past decade, the world has seen rapid growth in China’s biopharmaceutical, vaccine, cell and gene therapy markets. The speed of approval of biosimilar drugs and investment by the government to make more affordable drugs available to its people is accelerating that growth. Accordingly, the market for cell culture media in China has been expanding, and it is currently expected to grow at an annual rate of about

BILLINGHAM, UK, ― FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, viral vaccines and viral vectors, has confirmed a £400 million planned investment package at its UK facility in Billingham, Teesside. This investment package more than doubles the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom1 and is expected to create up to 350 highly-skilled jobs. The new facilities are expected to be operational by late 2023. The new multi-modal campus will include two new state-of-the-art facilities (a viral gene therapy GMP2 facility and a GMP mammalian cell culture facility) and is part of a ¥90 Billion Yen global capital investment package initially outlined by FUJIFILM Corporation in June 2021. The investment will add a new cell culture facility in the expanded Billingham campus and triple existing cell culture capacity capabilities at the site with the

The new, state-of-the-art facility will be located in Holly Springs, North Carolina Holly Springs, NC, October 14, 2021― FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, held a groundbreaking ceremony today to celebrate the start of its large-scale cell culture expansion project, funded by a major capital investment of $2 Billion USD from FUJIFILM Corporation (previously announced in January 2021). North Carolina Governor Roy Cooper announced Holly Springs, North Carolina as the selected location for the facility in March 2021, which is expected to be operational by spring 2025. The new site will bring 725 new jobs to the area by the end of 2028. The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors with the potential to expand and add a further 24 x 20,000L bioreactors based on

New European hub in Tilburg, the Netherlands, scheduled to open late 2021   SANTA ANA, California, September 29, 2021: FUJIFILM Irvine Scientific, Inc., today announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility and equipment in anticipation of full operations starting in late 2021. The new facility will join manufacturing locations in the U.S. and Japan to increase the production capacity of cell culture media products and provide a hub for European and global markets. Despite challenges to supply chain and operations caused by the COVID-19 pandemic, delivery of essential equipment and construction of the new Tilburg facility progressed throughout 2020. Completion of a third, state-of-the-art manufacturing facility is an important step in the Company’s long-term plans to ensure its production capacity can meet the growing needs of the market

Cambridge, Mass., and Madison, Wis. – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases, today announced that they have entered into a strategic research and development (R&D) alliance. As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on dry age-related macular degeneration (AMD) and inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells and photoreceptor cells, currently in pre-clinical development. There

Innovation and growth remain a priority to support customers and COVID-19 initiatives SANTA ANA, California – FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets. From its inception in the 1970s as a fetal bovine serum supplier, the Company has continuously provided pioneering cell culture solutions. In the 1980s it revolutionized embryo culture with commercially available media for in vitro fertilization (IVF) clinics worldwide. In the 1990s, the Company brought chemically defined media to biotherapeutic manufacturers. Most recently FUJIFILM Irvine Scientific launched products which better support cell culture-based vaccine production, and advanced cell and gene therapy applications. Since its acquisition by FUJIFILM Corporation, the Company has expanded its global reach and manufacturing capacity more rapidly.